MICROSONIC SYSTEMS INC — Department of Health and Human Services SBIR Phase I: 172

Description

DESCRIPTION provided by applicant Genetic analysis is a driving force behind andquot Personalized Medicineandquot and has become an essential tool in advancing all areas of biology medicine and behavioral biology As medical genetic sample analysis technology continues to develop there will eventually be a shift from the old paradigm of sending the sample out to the lab to point of care sample analysis Microsonic Systems Inc proposes to develop a rapid portable sample prep device for nucleic acid analysis using our Bulk Lateral Ultrasonic BLU Wave Transducer for point of care diagnostics Key to this instrument development will be the ability to rapidly perform multiple steps of nucleic acid sample prep in a single tube at cold andlt C temperatures Phase I specific aims include A optimization of the BLU energy parameters and nucleic acid extraction NAE protocol using normal frozen human muscle and skin tissues and B to evaluate and validate the optimized BLU energy nucleic acid extraction NAE protocol across normal and tumor samples from multiple human tissue types e g breast kidney prostate liver and thyroid Development of a point of care portable instrument Phase II to aid in detection treatment of oncology associated with these tissue groups is a potential paradigm shifting concept for the health care industry PUBLIC HEALTH RELEVANCE This project will leverage ultrasound technology being commercialized by Microsonic Systems Inc to development a rapid portable point of care sample prep instrument for determining multiple cancer biomarkers e g breast prostate kidney liver and thyroid and biomarkers for chronic kidney and thyroid diseases This will result in rapid patient diagnosis and management thus reducing delays in the diagnosis therapeutic cycle decreasing workload for various hospital departments and reducing overall health care costs